Cargando…
Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial
Immune dysregulation has been reported in schizophrenia spectrum disorders (SSD). In the past decade, several trials using anti-inflammatory agents for treatment of SSD have been completed, with so far limited success. One such anti-inflammatory agent used is simvastatin. A recent, large-scale, rand...
Autores principales: | Aichholzer, Mareike, Gangadin, Shiral S., Sommer, Iris E.C., Wijkhuis, Annemarie, de Witte, Lot D., Kahn, René S., Bahn, Sabine, Drexhage, Hemmo A., Schiweck, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668621/ https://www.ncbi.nlm.nih.gov/pubmed/36405425 http://dx.doi.org/10.1016/j.bbih.2022.100551 |
Ejemplares similares
-
Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
por: Sommer, Iris E, et al.
Publicado: (2021) -
Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers
por: Zaki, Jihan K., et al.
Publicado: (2022) -
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
por: Sommer, Iris E, et al.
Publicado: (2022) -
Association between gut permeability, brain volume, and cognition in healthy participants and patients with schizophrenia spectrum disorder
por: Scheurink, Toon Anton Willem, et al.
Publicado: (2023) -
Childhood trauma, suicide risk and inflammatory phenotypes of depression: insights from monocyte gene expression
por: Schiweck, Carmen, et al.
Publicado: (2020)